Literature DB >> 24816398

Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Kimberly L Samano1, Justin L Poklis2, Aron H Lichtman2, Alphonse Poklis3.   

Abstract

While Marijuana continues to be the most widely used illicit drug, abuse of synthetic cannabinoid (SCB) compounds in 'Spice' or 'K2' herbal incense products has emerged as a significant public health concern in many European countries and in the USA. Several of these SCBs have been declared Schedule I controlled substances but detection and quantification in biological samples remain a challenge. Therefore, we present a liquid chromatography-tandem mass spectrometry method after liquid-liquid extraction for the quantitation of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain. We report data for linearity, limit of quantification, accuracy/bias, precision, recovery, selectivity, carryover, matrix effects and stability experiments which were developed and fully validated based on Scientific Working Group for Forensic Toxicology guidelines for forensic toxicology method validation. Acceptable coefficients of variation for accuracy/bias, within- and between-run precision and selectivity were determined, with all values within ±15% of the target concentration. Validation experiments revealed degradation of CP-47, 497 and CP-47,497-C8 at different temperatures, and significant ion suppression was produced in brain for all compounds tested. The method was successfully applied to detect and quantify CP-47,497 in brains from mice demonstrating significant cannabimimetic behavioral effects as assessed by the classical tetrad paradigm.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816398      PMCID: PMC4148611          DOI: 10.1093/jat/bku043

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  34 in total

1.  Pharmacology of pravadoline: a new analgesic agent.

Authors:  D R Haubrich; S J Ward; E Baizman; M R Bell; J Bradford; R Ferrari; M Miller; M Perrone; A K Pierson; J K Saelens
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

2.  THC can be detected in brain while absent in blood.

Authors:  Patrick Mura; Pascal Kintz; Véronique Dumestre; Sébastien Raul; Thierry Hauet
Journal:  J Anal Toxicol       Date:  2005 Nov-Dec       Impact factor: 3.367

3.  Identification of a cannabinoid analog as a new type of designer drug in a herbal product.

Authors:  Nahoko Uchiyama; Ruri Kikura-Hanajiri; Nobuo Kawahara; Yuji Haishima; Yukihiro Goda
Journal:  Chem Pharm Bull (Tokyo)       Date:  2009-04       Impact factor: 1.645

4.  Chemical analysis of synthetic cannabinoids as designer drugs in herbal products.

Authors:  Nahoko Uchiyama; Ruri Kikura-Hanajiri; Jun Ogata; Yukihiro Goda
Journal:  Forensic Sci Int       Date:  2010-05-20       Impact factor: 2.395

5.  Disposition of cannabichromene, cannabidiol, and Δ⁹-tetrahydrocannabinol and its metabolites in mouse brain following marijuana inhalation determined by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Justin L Poklis; Candace C Thompson; Kelly A Long; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2010-10       Impact factor: 3.367

6.  Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol.

Authors:  A Weissman; G M Milne; L S Melvin
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

7.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

8.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

9.  Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry.

Authors:  R L Foltz; K M McGinnis; D M Chinn
Journal:  Biomed Mass Spectrom       Date:  1983-05

10.  Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.

Authors:  L S Melvin; G M Milne; M R Johnson; B Subramaniam; G H Wilken; A C Howlett
Journal:  Mol Pharmacol       Date:  1993-11       Impact factor: 4.436

View more
  2 in total

1.  Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Authors:  Travis W Grim; Kimberly L Samano; Bogna Ignatowska-Jankowska; Qing Tao; Laura J Sim-Selly; Dana E Selley; Laura E Wise; Alphonse Poklis; Aron H Lichtman
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

2.  The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice.

Authors:  Kristen R Trexler; S Olivia Vanegas; Justin L Poklis; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2020-07-15       Impact factor: 4.492

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.